• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Identification of novel and potential PPAR γ stimulators as repurposed drugs for MCAO associated brain degeneration
Toxicol Appl Pharmacol. 2022 May 9:116055. doi: 10.1016/j.taap.2022.116055. Online ahead of print.ABSTRACTPeroxisome proliferator-activated receptor-gamma (PPARγ) has been shown to have therapeutic promise in the treatment of ischemic stroke and is supported by several studies. To identify possible PPARγ activators, the current study used an in silico technique in conjunction with molecular simulations and in vivo validation. FDA-approved drugs were evaluated using molecular docking to determine their affinity for PPARγ. The findings of molecular simulations support the repurposing of rabeprazole and ethambutol for the ...
Source: Toxicology and Applied Pharmacology - May 13, 2022 Category: Toxicology Authors: Halima Usman Zhen Tan Mehreen Gul Sajid Rashid Tahir Ali Fawad Ali Shah Shupeng Li Jing Bo Li Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Peroxisome Proliferator-activated Receptor-γ Agonist Pioglitazone Ameliorates White Matter Lesion and Cognitive Impairment in Hypertensive Rats.
CONCLUSIONS: Long-term treatment of pioglitazone has beneficial effect on hypertension-induced WML and cognition decline, which may partly through its effect on attenuation of arteriolar remodeling, endothelial activation, and brain inflammation. PMID: 25611692 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - January 22, 2015 Category: Neuroscience Authors: Lan LF, Zheng L, Yang X, Ji XT, Fan YH, Zeng JS Tags: CNS Neurosci Ther Source Type: research